Adicet Bio Inc. (ACET)
| Bid | 0.86 |
| Market Cap | 71.2M |
| Revenue (ttm) | 11.7M |
| Net Income (ttm) | -106.93M |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | -0.69 |
| Analyst | Buy |
| Ask | 0.86 |
| Volume | 145,430 |
| Avg. Volume (20D) | 888,455 |
| Open | 0.91 |
| Previous Close | 0.90 |
| Day's Range | 0.85 - 0.91 |
| 52-Week Range | 0.81 - 2.54 |
| Beta | 1.64 |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...
Analyst Forecast
According to 5 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 478.64% from the latest price.
1 month ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
2 months ago · businesswire.com
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
2 months ago · businesswire.com
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical OfficerREDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...